0 seconds of 2 minutes, 16 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
02:16
02:16
 
  • Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251
  • The company has also announced a new chronic kidney disease research program
  • CEO Chris Moreau sat down with Shoran Devi to discuss the news
  • Algernon is a drug re-purposing company that investigates already approved drugs for new disease applications
  • Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55

Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (Repirinast).

The contract was awarded to Zhejiang Ausun Pharmaceutical CO, LTD of China.

Repirinast was originally marketed in Japan under the brand name Romet™ for the treatment of asthma.

The company has also announced a new chronic kidney disease research program.

CEO Chris Moreau sat down with Shoran Devi to discuss the news.

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Shares of Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.55.

More From The Market Online
Stock image generated with AI

@ the Bell: TSX finishes Friday lower but higher on the week

ended lower on Friday, driven by a drop in mining stocks amid concerns about the impact of trade tariffs on economic growth.
ai generated stock image.

@ the Bell: Did markets grow on the first day of spring?

TSX growth was driven by strong performances in the energy and financial sectors, supported by rising oil prices.
Cannabis nursery

Aurora makes breakthrough in cannabis mildew resistance

Aurora Cannabis (TSX:ACB) announces the discovery of PM2, a new source of genetic resistance for cannabis plants against powdery mildew.
Stock image generated with AI

@ the Bell: TSX rallies in the face of Fed’s interest-rate verdict

The TSX moved higher on Wednesday as investors braced for the US Federal Reserve's interest-rate verdict and contend with weak economic data.